Clinical trial
Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing…
NCT00362713 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00362713 |
|---|---|
| Title | Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection |
| Official title | A Phase 1b Safety and Dose-Assessment Study of Neoadjuvant Ipilimumab Monotherapy in Patients With Urothelial Carcinoma Undergoing Surgical Resection |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Urothelial Carcinoma |
| Intervention type | Drug |
| Interventions | Ipilimumab |
| Enrollment | 12 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Aug 10, 2006 |
| Last update posted | Sep 30, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: